Simultaneous Determination of Selegiline, Desmethylselegiline, R/S-methamphetamine, and R/S-amphetamine on Dried Urine Spots by LC/MS/MS: Application to a Pharmacokinetic Study in Urine by Lizhu Chen, Lizhu Chen, Yingjia Yu, Gengli Duan, Xin Wang, Baohua Shen, Ping Xiang

Subjects: Get full text

NLRP3–GABA signaling pathway contributes to the pathogenesis of impulsive-like behaviors and cognitive deficits in aged mice by Lu-Ying Wang, Xu-Peng Wang, Jin-Meng Lv, Yu-Dong Shan, Shi-Yan Jia, Zhi-Fang Yu, Hui-Tao Miao, Yue Xin, Dong-Xue Zhang, Li-Min Zhang

Subjects: Get full text

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST) by Michael Strupp, Grant C. Churchill, Ivonne Naumann, Ulrich Mansmann, Amani Al Tawil, Anastasia Golentsova, Nicolina Goldschagg

Subjects: Get full text

SIX-DAYS DYNAMICS ANXIETY INDEX OF FEMALE RATS WITH HIGH LEVEL OF ANXIETY IN BLOCKADE OF MAO-B by Denis R. Khusainov, Albina N. Lukyanceva, Natalya S. Tribrat, Elena A. Biryukova, Elena N. Chuyan, Ivan I. Korenyuk, Karine N. Tumanyants, Ekaterina V. Kashutina

Subjects: Get full text

Differences in CSF Biomarkers Profile of Patients with Parkinson's Disease Treated with MAO-B Inhibitors in Add-On by Henri Zenuni, Niccolò Candelise, Piergiorgio Grillo, Clara Simonetta, Roberta Bovenzi, Alberto Ferri, Cristiana Valle, Nicola Biagio Mercuri, Tommaso Schirinzi

Subjects: Get full text

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system by Hiroto Asano, Yu-Shi Tian, Asuka Hatabu, Tatsuya Takagi, Mikiko Ueda, Kenji Ikeda

“…Abstract Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. …”
Get full text

Dose- and application route-dependent effects of betahistine on behavioral recovery and neuroplasticity after acute unilateral labyrinthectomy in rats by Melissa Antons, Magdalena Lindner, Magdalena Lindner, Eva Eilles, Lisa Günther, Astrid Delker, Christina Branner, Anja Krämer, Roswitha Beck, Rosel Oos, Max Wuehr, Sibylle Ziegler, Michael Strupp, Michael Strupp, Andreas Zwergal, Andreas Zwergal

“…When compared to sham treatment, movement distance in the open field increased up to 5-fold from 2 to 30 days post-UL in the s.c., i.v. high-dose, and p.o. betahistine/selegiline groups. [18F]-FDG-μPET showed a dose-dependent rCGM increase in the ipsilesional vestibular nucleus until day 3 post-UL for i.v. high- vs. low-dose betahistine and sham treatment, as well as for p.o. betahistine/selegiline and s.c. betahistine vs. sham treatment. …”
Get full text

Inhibition of MAOB Ameliorated High-Fat-Diet-Induced Atherosclerosis by Inhibiting Endothelial Dysfunction and Modulating Gut Microbiota by Zhen Tian, Xinyue Wang, Tianshu Han, Maoqing Wang, Hua Ning, Changhao Sun

“…Finally, 16S rRNA sequencing showed that selegiline significantly altered the community compositional structure of gut microbiota. …”
Get full text

Effect of MAO-B Inhibitors on Neurometabolic Profile of Patients Affected by Parkinson Disease: A Proton Magnetic Resonance Spectroscopy Study by Lilla Bonanno, Rosella Ciurleo, Silvia Marino, Claudio Ruvolo, Rosa Morabito, Alessia Bramanti, Francesco Corallo

“…The aim of this longitudinal study is to evaluate the influence of rasagiline and selegiline on neurometabolic profile in de novo PD patients by using Proton Magnetic Resonance Spectroscopy (¹H-MRS). …”
Get full text

Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review by Takashi Tsuboi, Yuki Satake, Keita Hiraga, Katsunori Yokoi, Makoto Hattori, Masashi Suzuki, Kazuhiro Hara, Adolfo Ramirez-Zamora, Michael S. Okun, Masahisa Katsuno

“…Overall, rasagiline and safinamide had more published evidence on QOL and NMS changes compared with selegiline. This was likely impacted by selegiline being introduced many years prior to the field embarking on the study of NMS. …”
Get full text

Betahistine Treatment in a Cat Model of Vestibular Pathology: Pharmacokinetic and Pharmacodynamic Approaches by Brahim Tighilet, Jacques Léonard, Isabelle Watabe, Laurence Bernard-Demanze, Laurence Bernard-Demanze, Michel Lacour

“…Co administration of selegiline and betahistine increased values of Cmax and AUC up to 146- and 180-fold, respectively. …”
Get full text

Blocking Astrocytic GABA Restores Synaptic Plasticity in Prefrontal Cortex of Rat Model of Depression by Ipsit Srivastava, Erika Vazquez-Juarez, Lukas Henning, Marta Gómez-Galán, Maria Lindskog

“…The tonic inhibition can be reduced by either blocking astrocytic intracellular Ca²⁺ signaling or by reducing astrocytic GABA through inhibition of the synthesizing enzyme MAO-B with Selegiline. Blocking GABA synthesis also restores the impaired synaptic plasticity in the FSL prefrontal cortex, providing a new antidepressant mechanism of Selegiline.…”
Get full text

Activity of an oleanane-type tritrepenoid saponin from A. glycyphyllos on human recombinant MAO enzymes by Aleksandar Shkondrov, Magdalena Kondeva-Burdina, Ivan Stambolov, Ilina Krasteva

“…On the activity of hMAOA, the saponin had no effect, but on hMAOB, it exhibited statistically significant inhibition in comparison to the control, Selegiline. The compound could have potential in other models, so further investigations are required.…”
Get full text

Altered states, alkaloids, and catatonia: Monoaminoxidase inhibitors and their role in the history of psychopharmacology by Octavian Buda, Sorin Hostiuc, Ovidiu Popa-Velea, Steluta Boroghina

“…We will be focusing on banisterine, iproniazid, selegiline, rasagiline, tranylcypromine, moclobemide, and their role in the history of psychopharmacology. …”
Get full text

Different types of akathisia: clinical analysis on three cases by Lei WANG, Ming-yu WANG, Jin-long WU, Yun LI, Chi ZHONG

“…After alprazolam and propranolol were added, while anti-PD drugs (levodopa and benserazide, selegiline and pramipexole) continued to be applied, the symptoms were alleviated. …”
Get full text

Clinical neurorestorative progress in Parkinson's disease by Chen L, Huang HY, Duan WM, Mao GS

“…Currrently available novel clinical neurorestorative strategies include pharmacological managements (glial cell-line derived neurotrophic factor, selegiline, recombinant human erythropoietin), neuromodulation intervention (deep brain stimulation, repetitive transcranial magnetic stimulation, transcranial direct current stimulation), tissue and cell transplantation (fetal ventral mesencephalic tissue, sympathetic neurons, carotid body cells, bone marrow stromal cells, retinal pigment epithelium cells), gene therapy, and neurorehabilitative therapy. …”
Get full text

Serotonin syndrome induced by anti-parkinsonism drugs：a case report by WU Dongdong, LI Shuhua, SU Wen, LIU Yinghong, CHEN Haibo, CHEN Di

“…After combining his clinical manifestations with his history of concomitant medication, the doctors found that the patient had overdosed on selegiline and had an adverse reaction with anti-infective drug linezolid. …”
Get full text

Neuroprotective and MAOB inhibitory effects of a series of caffeine-8-thioglycolic acid amides by Alexandra Kasabova-Angelova, Magdalena Kondeva-Burdina, Javor Mitkov, Maya Georgieva, Virginia Tzankova, Alexander Zlatkov

“…They inhibited the enzyme by 23% and 25% respectively, thus approaching the selegiline activity, which was 42%. The possible mechanisms of neuroprotection of JTA-1 and JTA-2 might be a result from the inhibition of hMAOB, which catalyze the production of neurotoxic p-quinone from 6-OHDA.…”
Get full text

Family case of aromatic L-amino acid decarboxylase deficiency by O. B. Kondakova, K. A. Kazakova, A. A. Lyalina, N. V. Lapshina, A. A. Pushkov, N. N. Mazanova, Yu. I. Davydova, D. I. Grebenkin, I. V. Kanivets, K. V. Savostyanov

“…The patient’s condition was improved by using of combination therapy with pyridoxal‑5‑phosphate, pramipexole and selegiline. Significant positive dynamics was achieved on pyridoxal‑5‑phosphate therapy for the first time.…”
Get full text

Effectiveness of Integrative Therapy for Parkinson’s Disease Management by Yeonju Woo, Min Kyung Hyun

“…Sex, age, index year, comorbidity, severity of disability, neurologic care, and anti-parkinsonism medication (levodopa, ropinirole, pramipexole, selegiline) were adjusted in both groups. The prevalence of hospitalization due to pneumonia/sepsis was 0.50 times (95% C.I.: 0.26–0.96) lower in the integrative therapy group than the monotherapy group, which was statistically significant (p = 0.038). …”
Get full text